New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
Toshifumi TadaTakashi KumadaAtsushi HiraokaKazuya KariyamaJoji TaniMasashi HirookaKoichi TakaguchiMasanori AtsukawaShinya FukunishiEi ItobayashiKunihiko TsujiKazuto TajiriHironori OchiToru IshikawaSatoshi YasudaChikara OgawaHidenori ToyodaTakeshi HatanakaTakashi NishimuraSatoru KakizakiKazuhito KawataNoritomo ShimadaFujimasa TadaKazuhiro NousoAkemi TsutsuiHideko OhamaAsahiro MorishitaTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiHisashi KosakaMichitaka ImaiAtsushi NaganumaShinichiro NakamuraYohei KoizumiMasaki KaiboriHiroko IijimaYoichi Hiasanull nullPublished in: Cancer medicine (2022)
The neo-GPS can predict prognosis in advanced unresectable HCC patients treated with Atez/Bev.